Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking

Published by: Decision Resources

Published: May. 6, 2009 - 24 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

What Market Awaits Innovative Therapies?

Novel Approaches to Inflammation/Autoimmune Disease Treatment

Novel Targets

MAP Kinases
Jak

Toll-Like Receptors

Novel Interleukins
Nuclear Factor-Kappa B
Phosphodiesterase 4

Novel Technologies

RNA-Based Therapeutics

Stem-Cell Therapy

Company Profiles

Archemix

Array BioPharma

Cellzome

Dynavax

Regulus Therapeutics

Outlook

Tables

1. Descriptions of Inflammatory and Autoimmune Diseases

2. Top-Selling Autoimmune and Anti-Inflammatory Treatments, 2008

3. Common Immune Treatments and their Targets

4. MAP Kinase Agents in Clinical Development for Autoimmune and Inflammatory Diseases

5. Jak Kinase Agents in Development for Autoimmune and Inflammatory Diseases

6. Toll-Like Receptor Agents in Development for Autoimmune and Inflammatory Diseases

7. IL-12, IL-17, and IL-23 Agents in Development for Autoimmune and Inflammatory Diseases

8. NF-ęB Agents in Development for Autoimmune and Inflammatory Diseases

9. PDE4 Agents in Development for Autoimmune and Inflammatory Diseases

10. Select Deals in Autoimmune and Inflammatory Disease Drug Development

11. Select Academic Collaborations in Autoimmune and Inflammatory Disease Drug Development

Figures

1. Worldwide Sales of Agents to Treat Inflammatory and Autoimmune Diseases, 2003-2008

2. Market Share of the Autoimmune and Inflammatory Disease Market by Company, 2008

Abstract

Introduction

Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.

Get the Answers You Need to Shape Your Strategy
  • Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully
    • treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
  • Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat inflammatory diseases? What collaborations have they forged with Big Pharma?
  • Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology
    • of many diseases remains unknown. What are companies doing to further the understanding of these diseases?
Scope
  • Current market: 2008 sales, market-leading products, leading companies.
  • Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors,novel interleukins, NF-ęB, PDE4.
  • Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
  • Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
  • Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009